Over-activity of the immune system is a primary cause of many diseases, both common and rare. Afecta is focused on developing new drugs to selectively suppress specific pro-inflammatory pathways involved in dermatologic disorders as well as other related diseases. We have used our novel technology platform, PharmetRx™, to discover several classes of new small molecules based on compounds that are proven to be safe. We are using novel formulation technologies to improve delivery of these lead drugs to specifically and directly target the affected tissues, thus minimizing systemic effects. These "de-risked" lead drug candidates are being moved into our clinical development pipeline.